Free Trial

Alkermes (ALKS) Stock Forecast & Price Target

Alkermes logo
$27.91 +0.43 (+1.56%)
(As of 11/20/2024 ET)

Alkermes - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
3
Buy
8

Based on 12 Wall Street analysts who have issued ratings for Alkermes in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 3 have given a hold rating, and 8 have given a buy rating for ALKS.

Consensus Price Target

$35.42
26.90% Upside
According to the 12 analysts' twelve-month price targets for Alkermes, the average price target is $35.42. The highest price target for ALKS is $50.00, while the lowest price target for ALKS is $25.00. The average price target represents a forecasted upside of 26.90% from the current price of $27.91.
Get the Latest News and Ratings for ALKS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Alkermes and its competitors.

Sign Up

ALKS Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$35.42$36.70$36.70$32.29
Forecasted Upside26.90% Upside30.60% Upside31.31% Upside32.43% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ALKS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALKS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alkermes Stock vs. The Competition

TypeAlkermesMedical CompaniesS&P 500
Consensus Rating Score
2.58
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside26.90% Upside26,931.53% Upside9.83% Upside
News Sentiment Rating
Positive News

See Recent ALKS News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/13/2024Mizuho
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$35.00 ➝ $40.00+36.85%
11/5/2024Stifel Nicolaus
4 of 5 stars
 UpgradeHold ➝ Buy$25.00 ➝ $36.00+35.39%
10/25/2024The Goldman Sachs Group
2 of 5 stars
 Lower TargetBuy ➝ Buy$32.00 ➝ $30.00+13.55%
10/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$32.00 ➝ $26.00-1.44%
10/25/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$48.00 ➝ $43.00+63.00%
10/25/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$38.00 ➝ $37.00+42.09%
10/25/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$37.00 ➝ $37.00+37.80%
7/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$37.00 ➝ $38.00+43.34%
6/17/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Thome
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$34.00+38.78%
4/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$42.00 ➝ $50.00+87.62%
2/20/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$25.00-22.31%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$27.00 ➝ $29.00+0.55%
10/24/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:37 AM ET.


ALKS Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Alkermes is $35.42, with a high forecast of $50.00 and a low forecast of $25.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There is currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares.

According to analysts, Alkermes's stock has a predicted upside of 26.90% based on their 12-month stock forecasts.

Over the previous 90 days, Alkermes's stock had 1 upgrade by analysts.

Alkermes has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Mizuho, Piper Sandler, Stifel Nicolaus, and The Goldman Sachs Group in the past 90 days.

Analysts like Alkermes less than other "medical" companies. The consensus rating score for Alkermes is 2.58 while the average consensus rating score for "medical" companies is 2.80. Learn more on how ALKS compares to other companies.


This page (NASDAQ:ALKS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners